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ABSTRACT
Laser-assisted drug delivery augments the dis-
tribution and penetration of topically applied
treatments, leading to enhanced delivery and
bioavailability. We discuss the therapeutic
application of laser-assisted drug delivery in
clinical practice in cases of non-melanoma skin
cancer, vitiligo, melasma, scarring, and alopecia
(female pattern hair loss, male pattern hair loss,
alopecia areata) as well as for vaccination, local
anaesthesia, analgesia, viral warts, infantile
haemangiomas and cosmetic uses, and we
review clinical studies that have used this
technique over the last decade. Our review
shows that the application of laser-assisted drug
delivery enhances topical agent efficacy,
potentially reducing the agent concentration
and duration of topical treatment required.
Future research into the use of laser-assisted
drug delivery before topical therapies is needed
to establish the optimal techniques to enhance
drug delivery and thus improve patient
outcomes.
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Key Summary Points
Laser-assisted drug delivery augments the
distribution and penetration of topically
applied treatments, leading to enhanced
delivery and bioavailability.
Laser-assisted drug delivery is used
therapeutically in clinical practice in cases
of non-melanoma skin cancer, vitiligo,
melasma, scarring, alopecia (female
pattern hair loss, male pattern hair loss,
alopecia areata) as well as for vaccination,
local anaesthesia, analgesia, viral warts,
infantile haemangiomas and cosmetic
uses.
We found that laser-assisted drug delivery
enhanced the efficacy of topical agents,
potentially reducing the agent
concentration and duration of topical
treatment required.
Future research into the use of laser-
assisted drug delivery before topical
therapies is needed to establish the
optimal techniques to enhance drug
delivery and thus improve patient
outcomes.
DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. You can
access the digital features on the article’s asso-
ciated Figshare page. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.13378829.
INTRODUCTION
Topical medications undergo limited epidermal
absorption due the robustness of the skin bar-
rier. Laser-assisted drug delivery (LADD)
involves the use of an ablative fractional laser,
namely a carbon dioxide (CO2) or erbium-
doped yttrium aluminium garnet (Er:YAG)
laser, to create microscopic channels that allow
drugs to travel through the epidermis [1, 2].
Er:YAG and CO2 lasers are both ablative, but
with different ablation-to-coagulation ratios
depending on the biological interaction.
Er:YAG laser light has a much higher absorption
coefficient in water than CO2 laser light, leading
to a higher ablation-to-coagulation ratio and a
shallower depth of penetration, although this
also depends on the laser fluence and beam spot
size. While both lasers are equally effective at
providing a path for therapeutic agents through
the stratum corneum, the CO2 laser, with its
deeper beam profile and coagulative zone, is
preferable to the Er:YAG laser for more pene-
trative beam dermal drug delivery.
Ablative laser devices have been utilised in
patients with a range of conditions to facilitate
drug delivery through skin layers. This tech-
nique enables high molecular weight molecules
to pass through the stratum corneum. Ablative
fractional laser technology (AFXL) works
through photothermolysis: tissue is destroyed
in multiple skin layers, starting with the stra-
tum corneum. The depth of the tissue that is
destroyed by the laser depends on the laser
parameters employed. The resulting channel
through the skin is encapsulated by a micro-
scopic treatment zone that enables the pene-
tration of topical molecules into the skin layer
to be treated, resulting in faster healing with
less scarring [3].
This article focuses on the use of ablative
laser devices to enhance the delivery of drugs
that are used to treat a variety of conditions.
The most recent advances in this field are
reviewed. The article only considers previously
conducted studies; it does not discuss any new
studies with human participants or animals
performed by any of the authors.
Non-melanoma Skin Cancers and Skin
Cancers
Actinic Keratoses
Actinic keratoses (AKs) are premalignant lesions
that can be considered part of the non-me-
lanoma skin cancer (NMSC) family [5, 6].
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Treatment options for AKs include cryotherapy,
curettage, excision, photodynamic therapy
(PDT), topical 5-fluorouracil, and imiquimod. A
recent systematic review noted that when
AFLX-assisted PDT was employed to treat AK,
the 12-month AK clearance rate increased from
45–51% (for non-AFXL-assisted PDT) to 78–85%
[7].
PDT monotherapy was compared with AFXL
pretreatment followed by PDT (10 mJ per pulse,
0.12 mm spot, 5% density) in a trial of 15
patients with AKs. After three months of follow-
up, the AFXL-PDT therapy was found to be
more efficacious than PDT monotherapy, pro-
ducing a complete lesion response in 88% of
patients, as compared to 59% for PDT
monotherapy. Nevertheless, side effects such as
erythema, crusting, pigmentation and pain
occurred more frequently in patients who
received the AFXL-PDT treatment than in those
who underwent the PDT monotherapy. This
study suggests that although AFXL augments
the penetration of PDT, side effects are more
pronounced when this pretreatment is applied
[8].
Patients who receive organ donations are at
greater risk of AKs and other NMSCs, and the
resulting lesions are less responsive to PDT [6].
AFXL-PDT (30 W, 0.12 mm spot size, two pas-
ses) was compared with AFXL alone for the
treatment of ten transplant patients with AKs.
73% of the AFXL-PDT group had a complete
response, compared with 31% of the AFXL
monotherapy group [9].
In a separate study of 46 patients, 22 received
PDT whilst 24 underwent AFXL-PDT. Both
groups were then treated with the photosensi-
tiser methyl aminolevulinate (MAL; incubation
for 90 min). Clearance rates at 10 weeks were
64.7% in the PDT-only group and 71.4% in the
AFXL-PDT group, which was not indicative of a
significant difference in clearance between the
groups. This study suggests that AFXL pretreat-
ment could reduce the incubation time needed
for the photosensitiser without affecting effi-
cacy [10].
A recent case report presented two patients
with multiple AKs who received single sessions
of Er:YAG laser ablation (Etherea, Vydence
Medical Sao Paulo, Brazil; wavelength:
2940 nm, spot size: 8 mm, density: 100 MTX/
cm2, single mode (500 ls), energy: 12.5 mJ/
MTZ). This treatment was followed by a com-
bination of 5% 5-FU and 2% alpha-bisabolol for
six nights. The patients presented excellent
clinical responses, with complete lesion clear-
ance and improved skin quality, and this
response was maintained at nine months of
follow-up [11].
These studies suggest that pretreatment with
AFXL could enhance the penetration of topical
therapies such as 5-FU or imiquimod that are
used to treat AKs and other NMSCs. It could also
reduce the number of therapeutic sessions
required, which would be particularly helpful
for patients who are less compliant or have
multiple difficult-to-reach lesions [12].
Bowen’s Disease
Bowen’s disease is a type of squamous cell car-
cinoma in situ in which there is full-thickness
dysplasia of the epidermis. If left untreated,
Bowen’s disease can progress into squamous cell
carcinoma (SCC). AFXL pretreatment of
Bowen’s disease preceding MAL-PDT has been
shown to shorten the photosensitiser incuba-
tion time required to achieve the same effi-
ciency (70 min compared to the typical
180 min) [13].
A systematic review investigating AFXL-as-
sisted treatments for keratinocyte carcinoma
and its precursors found that the 12-month
clearance rate of Bowen’s disease increased from
50–55% to 88% with AFXL-assisted therapy. [7]
A randomised controlled trial of 21 patients
with multiple Bowen’s disease lesions had a
clearance rate of 93.8% three months after a
single AFXL-PDT treatment, compared with
73.1% three months after the first of two ses-
sions of MAL-PDT. The 12-month relapse rate
was also significantly lower for AFXL-PDT
(6.7%) than for MAL-PDT (31.6%) [14].
In a separate case series of 28 patients with
Bowen’s disease, patients were treated with a
single session of CO2-AFXL (0.12 mm spot size,
10 mJ per pulse, single pulse, 5% density) fol-
lowed by one application of topical 5% 5-FU
under occlusion for 7 days. It was reported that
100% of the Bowen’s disease lesions had cleared
histologically after 8 weeks [15].
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Basal Cell Carcinoma
PDT therapy is not typically recommended for
nodular BCCs because penetration is often
limited by the thickness of the tumour itself
[16]. Pretreatment with AFXL is hypothesised to
create channels for a photosensitising agent to
reach the tumour [2].
A case series of three patients with nodular
BCCs were treated with AFXL prior to MAL-PDT
treatment. Two patients presented complete
clinical and histological responses; the third
had a partial response, probably because that
patient had a sclerosing tumour subtype for
which PDT is less effective. Randomised con-
trolled trials are needed to investigate the use of
AFXL in the pretreatment of BCC [17].
A separate study investigated nodular BCCs
treated with a 980-nm gallium arsenide diode
laser under ultrasound control (n = 56) [18].
After 3 weeks, each BCC was divided in half,
with one half receiving CO2-AFXL and the other
half receiving curettage followed by ALA-PDT
therapy. Clearance rates (confirmed histologi-
cally) were greater for the halves treated with
AFXL (93%) than for the halves that underwent
curettage (80%).
In another study, 32 patients were ran-
domised to receive AFXL-PDT or conventional
MAL-PDT for the treatment of histologically
confirmed high-risk nodular BCCs [19]. A 100%
cure rate was achieved at 3 months when a CO2-
AFXL-PDT (5% density, 80 mJ, 1000 lm abla-
tion depth) treatment was used, as compared
with an 88% cure rate for those treated with
conventional PDT. Nevertheless, the histologi-
cal tumour clearance rates for both therapies
after 12 months were comparable.
Actinic Cheilitis
Patients with actinic cheilitis (n = 33) were
randomised to receive either one session of
AFXL-PDT or two sessions of MAL-PDT [20].
92% of those treated with AFXL-PDT showed a
complete response after three and twelve
months, as compared with 59% of those treated
with MAL-PDT. There was no significant differ-
ence between the side-effect profiles for the two
treatments. This study supports the possible use
of AFXL with PDT in cases of actinic cheilitis.
PDT is not usually as effective for actinic
cheilitis as it is for AKs, although both condi-
tions present a similar risk of subsequent squa-
mous cell carcinoma development [21].
Pigmentary Disorders
Vitiligo
Recalcitrant vitiligo patients (n = 25) were trea-
ted on one side of the body with CO2-AFXL
(every 2 weeks) followed by betamethasone
topical solution under occlusion followed by
narrowband-ultraviolet B (NB-UVB) photother-
apy (2–3 times a week for 6 months), and on the
other (control) side of the body with CO2-AFXL
and NB-UVB alone [22]. Over 50% repigmenta-
tion occurred in 44% of the betamethasone-
treated sides, which was significantly greater
than the corresponding rate for the control
sides, due to greater corticosteroid penetration.
However, the length of treatment and the sig-
nificant cost may make this treatment course
less suitable for parsimonious healthcare sys-
tems [22].
Melasma
Tranexamic acid has been used for a wide vari-
ety of skin conditions, including melasma [23].
A split-face, double-blind, randomised con-
trolled study of 46 melasma patients treated
with a 1927-nm thulium laser on both sides of
the face and with tranexamic acid on one side
of the face was reported. Significant improve-
ments were observed on both face sides, and
there was no statistically significant difference
in improvement between the sides [24]. Similar
findings were reported for a randomized com-
parative split-face study of 30 melasma patients
treated with a fractional ablative CO2laser alone
or in combination with tranexamic acid [25].
Both the combination therapy and the
monotherapy resulted in a significant reduction
in the Melasma Area and Severity Index (MASI).
Patients reported no difference in improvement
between the face sides, but the degree of
improvement in the MASI score was greater for
the side that was treated with the fractional
ablative CO2 laser only. The use of tranexamic
acid in combination with fractional ablative
CO2 laser treatment requires further
96 Dermatol Ther (Heidelb) (2021) 11:93–104
investigation [25]. A separate study compared
microneedling on one side of the face with
fractional CO2 laser treatment in combination
with tranexamic acid on the other side of the
face in 30 melasma patients, and found no sta-
tistically significant difference between the
sides [26]. A randomized, single-blinded, split-
face clinical trial of 40 melasma patients treated
with topical hydroquinone 4% or a combina-
tion of topical hydroquinone 4% and a frac-
tional laser noted improvements in
hyperpigmentation and darkness on both face
sides, with no significant difference in
improvement between sides [27]. The use of an
Er:YAG laser to enhance topical hydroquinone
penetration was investigated in 30 melasma
patients [28]. In a split-face study, patients were
treated on one side with six sessions involving
the application of a fractional Er:YAG laser and
then 4% hydroquinone cream, with a 2-week
interval between each session, and on the other
side with the 4% hydroquinone cream alone.
Pretreatment with the Er:YAG laser led to sig-
nificantly better results (much larger reductions
in the MASI) than using hydroquinone alone
[28]. A recent split-face study of 22 patients with
melasma compared the effects of a fractional
Er:YAG laser combined with a topical steroid to
the effects of fractional Er:YAG monotherapy
[29]. Significantly better outcomes were
achieved with the combined therapy, with the
MASI score decreasing much more than in the
Er:YAG monotherapy group [29].
Anaesthesia and Analgesia
Local Anaesthetics
Many dermatological surgical procedures
require a local anaesthetic. Topical anaesthetic
agents may not penetrate deeply enough, whilst
injections are associated with discomfort [2].
The application of an Er:YAG laser prior to
the use of topical 4% lidocaine was found to
reduce the pain associated with injection in as
little as 5 min when compared to the applica-
tion of the laser and placebo (reduction of 62%)
or lidocaine monotherapy (61% reduction) [30].
A randomised controlled trial of 61 patients
who underwent cannulation in A&E found that
pain levels were significantly lower when a
Er:YAG laser was used before topical 4% lido-
caine [31].
These findings were replicated by Meesters
and colleagues, who found that pretreatment of
ten patients with CO2-AFXL (5% density,
2.5 mJ/microbeam) prior to the application of
topical local anaesthetics such as articaine
hydrochloride 40 mg/ml, adrenaline 10 lg/ml
solution (AHES) and lidocaine 25 mg/
g with prilocaine 25 mg/g cream (EMLA
cream) was painless [32]. Self-reported pain
levels due to a painful stimulus were signifi-
cantly lower following the application of AFXL
and these topical local anaesthetics than fol-
lowing a sham laser therapy. AHES plus AFXL
was found to be the most efficacious anaesthetic
method, likely due to the liquidity of this
treatment option [32].
In a randomised controlled trial, twelve
patients were treated on one side of the face
with a low-fluence Er:YAG laser prior to the
application of 5% topical lidocaine and whole-
face resurfacing in two sessions [33]. Self-re-
ported pain scores were significantly less for the
side pretreated with the Er:YAG laser, although
only 56% of patients were able to tolerate the
second resurfacing treatment [33].
Analgesia
The effect of AFXL on diclofenac penetration
was investigated by Bachhav and colleagues.
The permeation of diclofenac depended on the
pore frequency and the laser fluence used.
Clinically, the results of this study indicate that
AFXL pretreatment of the skin is an effective
method of augmenting the local absorption of
topical diclofenac while avoiding systemic side
effects such as gastric complications and renal
problems [22].
Similarly, systemic side effects of opioids
could be avoided by applying topical agents in
conjunction with Er:YAG laser pretreatment.
This has only been investigated in animal
studies, so human trials are required to examine
its potential for clinical use [30].
Dermatol Ther (Heidelb) (2021) 11:93–104 97
Scarring
AFXL treatment can remove sections of fibrotic
scars, normalising collagen structure and com-
position and improving overall scar appearance
[34], and is applicable to keloids [35] and
hypertrophic scars[ 36].
In one study, 15 patients with hypertrophic
scars received up to five treatments with CO2-
AFXL (10–15% density) followed by topical tri-
amcinolone (10 or 20 mg/ml) [36]. After 6
months, improvements in texture, hypertrophy
and dyschromia were noted. AFXL treatment
permitted greater uniformity of the depth and
distribution of triamcinolone and bypassed the
pain often associated with intralesional injec-
tions [36]. In a prospective double-blinded
study of 20 patients with hypertrophic scars, the
patients had three treatment sessions every
month with CO2-AFXL followed by postopera-
tive treatment with either triamcinolone ace-
tonide (20 mg/mL) or topical 5-fluorouracil
(50 mg/mL). There were no statistically signifi-
cant differences between these treatments, but
treatment of the scars with 5-fluorouracil did
not result in the side effects associated with
corticosteroid therapy, such as dermal atrophy
and telangiectasia [37].
A double-blind, randomised, split-face trial
investigated postoperative wound healing. Fif-
teen patients were treated with a vitamin C, E
and ferulic acid serum on one side of the face
and a vehicle cream on the other side immedi-
ately after the application of a fractional abla-
tive CO2 laser. Decreased postoperative oedema
and erythema were noted for the face sides
treated with the laser, as well as significantly
increased expression of basic fibroblast growth
factor, indicating that wound healing was more
rapid with this treatment [38].
In a separate study, 23 patients with 70
keloid scars were treated with Er:YAG-AFXL
(180 J/cm2, 5% coverage) every other week and
concomitant betamethasone cream twice daily
under occlusion until the scar was flattened or
no further improvement was observed [39].
After a median treatment time of nine sessions,
the patients showed a median 50% improve-
ment in scar appearance, and recurrence was
22% eight months following treatment [39].
Ten patients with keloid scars were treated
with an ablative Er:YAG laser (four treatments, 6
weeks between treatments) and then received
either an intralesional steroid injection or
topical corticosteroids under occlusion for 3 h
[40]. The combination of ablative fractional
Er:YAG laser treatment and topical corticos-
teroids resulted in greater decreases in the mean
keloid Vancouver Scar Scale score and the mean
pain score than in the corticosteroid injection
group [40].
A patient (Fitzpatrick VI) with a ten-year
history of keloid was treated with eight sessions
of CO2-AFXL immediately followed by laser-as-
sisted drug delivery of a topical triamcinolone
acetonide ointment. Excellent cosmetic results
were noted at the 22-month follow-up [41]. This
case emphasises the safety of AFXL in patients
with dark skin when it is used in the correct
setting [41].
Nineteen patients with atrophic scars were
treated with CO2-AFXL (spot size 120 lm, depth
375–500 lm, density 10%) followed by the
topical application of poly-L-lactic acid (PLLA;
Sculptra), which is often used as a filler due to
its proposed ability to stimulate fibroblast pro-
liferation [42]. After 3 months, improvements
in scar contours, atrophy and colour were
reported, with proposed mechanisms of action
including enhanced PLLA dermal penetration
[42].
Cosmetic Uses
A split-face study investigated 14 patients with
signs of photoageing [43]. Both sides of the face
were first pretreated with CO2-AFXL. After that,
PixelTreatSR serum (Alma Lasers, Caesarea,
Israel) was applied to one half of the face,
immediately followed by ultrasound pulses to
stimulate transepidermal passage. The serum
was composed of keratolytics, lipids, vitamins
and bioactive peptides. At six months,
improvements in pigmentation, fine lines and
wrinkles, and overall ageing on the side that
received the serum were noted. It is unclear
whether this improvement was due to the
ultrasound or the serum, but the results of this
study support the use of AFXL-assisted cosme-
ceuticals in cosmetic dermatology [43].
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A separate split-face study of ten patients
investigated the use of CO2-AFXL in combina-
tion with topical botulinum neurotoxin type A
(BoNTA) on one side of the face and a saline
control on the other side [44]. The side with
BoNTA showed significant reductions in peri-
orbital wrinkles at one week and one month
post-treatment, suggesting that the delivery of
BoNTA could be augmented by AFXL pretreat-
ment. This method of delivering BoNTA could
potentially avoid the pain, discomfort, ery-
thema and infection risk associated with BoNTA
injections [44]. Future studies comparing
BoNTA injections with different topical BoNTA
compositions must be carried out to explore the




A study investigated the use of a nonablative
erbium glass fractional laser (eight sessions at
7 mJ, 3–9% coverage, density 120 MZT/cm2)
followed by topical finasteride 0.05% and
growth factors (basic fibroblast growth factor,
insulin-like growth factor, vascular endothelial
growth factor, and copper peptide 1%) in four
patients with androgenetic alopecia [46].
Improved hair regrowth and density were
observed in all patients, with no significant
reported side effects [46]. Ablative laser therapy
could allow topical agents to be effectively
delivered to and distributed uniformly in the
dermis, where the majority of the hair follicles
are located [47]. A fractional CO2 laser was
applied along with a topical triamcinolone
spray (10 mg/mL) to ten patients with recalci-
trant alopecia areata. Seven of the eight patients
who finished the treatment experienced com-
plete recovery of the area treated [48]. Forty-five
male patients with androgenetic alopecia were
treated with an ablative fractional CO2 laser and
minoxidil combination, the fractional CO2 laser
alone, or minoxidil alone. The application of
the ablative fractional CO2 laser alone or in
combination with minoxidil produced the best
results [49].
Amyloidosis
The effect of AFXL treatment on macular amy-
loidosis was compared with the effect of AFXL-
assisted drug delivery of topical steroids and
vitamin C in ten patients with cutaneous mac-
ular amyloidosis, a type of primary localised
cutaneous amyloidosis. Patients underwent four
sessions of fractional CO2 laser treatment
(power 18 W, spacing 800 lm, dwell time
600 ls, stacking 3), with a 4-week interval
between sessions [50]. All targeted areas showed
significantly decreased pigmentation scores, an
improvement in lichenification, and decreased
histological amyloid after treatment. The area
treated with the fractional laser and corticos-
teroids demonstrated the largest decrease in
amyloid, highlighting the benefits of a frac-
tional CO2 laser in assisting the delivery of
topical steroids and topical vitamin C [50].
Vaccination
Intradermal delivery of vaccines can be more
efficacious than the conventional intramuscular
route due to the abundance of antigen-pre-
senting cells in the skin [51].
The use of AFXL (5–15% coverage) to
enhance the transcutaneous delivery of a model
antigen (ovalbumin, OVA), provoking an
immune response, has so far only been
demonstrated in animal studies. Further studies
of this response in humans are warranted, in
particular to address possible safety concerns
[51].
Haemangiomas
The utilisation of topical timolol for the treat-
ment of infantile haemangiomas (IHs) was
investigated in a study of nine children [52].
CO2-AFXL was applied weekly to the skin sur-
faces of deep IHs (25–30 mJ/pulse, 5% density,
single pulse), followed by a topical timolol
maleate solution (0.5%) under occlusion five
times a day for 14 weeks. 44% of patients had an
excellent response to this treatment, 44% had a
good response, and 11% had a moderate
response, measured via the haemangioma
activity score. Treatments were well tolerated,
with no reported side effects. This study’s find-
ings suggest that the application of AFXL
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pretreatment preceding topical timolol could be
an alternative for infants in which systemic
therapies are contraindicated, or for localised
IHs [52].
A recent study replicated these findings; it
investigated the treatment of 30 deep IHs with a
fractional Er:YAG laser applied at two-week
intervals and subsequent topical timolol mal-
eate 0.5% applied under occlusion for 30 min
four times a day for 24 weeks [53]. 76.7% of
patients showed excellent regression, 13.3%
had good regression, and 10% showed moderate
regression [53].
Viral Warts
A Korean study investigated 12 patients with 40
periungual warts treated with CO2-AFXL prior
to the application of PDT and MAL as well as red
light illumination 180 min later. Patients had
an average of 2.2 treatments per wart, with 90%
of the lesions presenting complete clinical
clearance and 5% exhibiting no apparent ther-
apeutic response [54]. A separate study investi-
gated the use of an Er:YAG ablative fractional
laser and topical cidofovir for the treatment of
recalcitrant plantar warts in two patients. Both
patients experienced a significant reduction in
lesion size and an improvement in symptoms
[55].
Primary Plantar Hyperhidrosis
Botulinum toxin type A (BTX-A) was used in
three patients with primary palmar hyper-
hidrosis. Immediately afterwards, a fractional
CO2 laser was applied; the resulting enhanced
delivery of BTX-A led to a decrease in sweat
production [56].
DISCUSSION
Large, robust randomised controlled trials are
required to demonstrate the benefit of AXFL
when used as a pretreatment for the conditions
described above, as well as to investigate any
possible associated side effects [57]. Demo-
graphic investigations, including those focusing
on age, gender and ethnicity, are also warranted
to assess the benefits of AXFL in different
patient subgroups. Laser parameters such as the
fluence, density, number of treatments and
treatment length must be optimised to max-
imise drug penetration and minimise skin
damage [2].
The literature supports the laser-assisted
delivery of anti-inflammatory, antineoplastic
and antioxidative agents to treat scarring, pho-
toageing and neoplasias [58]. Clinicians face
challenges such as unpredictable dosing and
therapeutic responses, the possibility of local
and systemic reactions, and inconsistent treat-
ment regimes [58].
The vehicle of choice, such as a gel, patch,
cream or ointment, as well as the length of
treatment, the frequency of use and the con-
centration of the drug must also be considered
[2]. Any side effects resulting from the increased
penetration of drugs designed for topical appli-
cation following the application of laser-assisted
delivery must not be overlooked, and care must
be taken when investigating this issue [2, 4]. A
cost–benefit analysis of AFXL pretreatment
must also be performed, and the efficacy of this
pretreatment must be substantiated before its
use over preestablished treatments can be war-
ranted [2].
Based on relevant studies, it appears that the
most important step in the treatment of most
superficially located pathologies is traversing
the stratum corneum, that the difference in
wavelength between CO2 and Er:YAG lasers is
not particularly significant, and that a relatively
low laser density is as effective for laser-assisted
delivery as a larger density. The depth of abla-
tion achieved with both lasers depends on the
device characteristics, such as the beam profile
and fluence used. Deeper dermal pathologies
require a channel that reaches the required
depth, which necessitates a higher laser fluence.
It should be noted that the literature in this
field includes more studies of the use of a CO2
rather than an Er:YAG laser due to the deeper
penetration profiles of currently available CO2
laser devices, as well as the possible added
advantage that the surrounding coagulative
zone acts as a slow-release reservoir for drug
release.
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CONCLUSIONS
Overall, current research suggests that AFXL
pretreatment enhances the penetration and
absorption of topical agents. The strongest evi-
dence of a benefit of AFXL pretreatment is
provided by the application of MAL-PFT to AKs,
which produces long-lasting results compared
with conventional PDT and no adverse effects
[59]. Therefore, the addition of AFXL pretreat-
ment to current therapies could make them
more efficacious, meaning that treatment
lengths could be shortened and active agent
concentrations could be weakened, reducing
the potential for side effects [60]. Future studies
involving larger patient cohorts will aim to
improve our understanding of this pretreatment
option and to optimise its parameters to achieve
the best possible patient outcomes.
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